Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Presbyopia: later-stage trial registry
9 of 39 indexed Presbyopia trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #382 of 28,707 conditions by registered trial count.
39 US clinical trials · 9 currently recruiting · #382 of 28,707 conditions by registered trial count
Presbyopia: 39 US clinical trials tracked, 9 recruiting.
Presbyopia is the subject of 39 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Alcon Research, running 6 of these trials.
Enrollment posture brief
Registry condition presbyopia
OPEN 9 | RECR 23% | LATE 7 | EARLY 3 | RANK #382 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Actinic Keratoses (23% recruiting · 13 trials)
Presbyopia lists 9 open slots (23% of 39 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Presbyopia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Presbyopia is recruiting below its size-band peers.
9 of 39 indexed trials (23.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Presbyopia research.
Alcon Research accounts for 6 of 39 trials (15.4%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Presbyopia trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 39 trials that report a genuine target (sentinel values excluded). 24 of those (61.5%) plan for fewer than 100 participants.
-
Presbyopia research is mostly interventional.
33 interventional and 6 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
39 total, page 1 of 1
Clinical Applications of Advanced Ophthalmic Imaging
University of Miami
NCT03135327
IC-8 Apthera IOL New Enrollment Post Approval Study
Bausch & Lomb Incorporated
NCT06060041
North American Comfilcon A Clinical Study
CooperVision International Limited (CVIL)
NCT06902584
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
Alcon Research
NCT07161635
Phase III Presbyopia Correction Using the VIS Opti-K™ System
VIS
NCT06487897
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
CooperVision International Limited (CVIL)
NCT06869044
Comfort and Vision With TOTAL30 Multifocal Lenses
Scripps Poway Eyecare and Optometry
NCT07284966
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
Southern College of Optometry
NCT07113210
Presbyopic Wear Experience With Multifocal Lenses Compared to Single Vision Lenses and Reading Glasses
Ohio State University
NCT07218731
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
Alcon Research
NCT05796453
Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement
Alanna Nattis, DO
NCT04570579
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Visus Therapeutics
NCT05135286
Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
AcuFocus
NCT03633695
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
LENZ Therapeutics
NCT05753189
Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes
AcuFocus
NCT00819299
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
Orasis Pharmaceuticals
NCT04599972
Handling Comparison Between Two Contact Lens Types
Johnson & Johnson Vision Care
NCT02310126
Assessing Fitting Guides in Alcon Multifocal Contact Lenses
Alcon Research
NCT03118934
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
Eyenovia
NCT05114486
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
Novartis Pharmaceuticals
NCT03809611
Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses
Alcon Research
NCT05338333
Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle
University of California, Berkeley
NCT01234207
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
Eyenovia
NCT04657172
Assessment of Three Basic Progressive Lens Designs
Western University of Health Sciences
NCT05252871
Monofocal IOL Visual Outcomes When Targeting Mini Monovision
Carolina Eyecare Physicians
NCT05069415
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
Johnson & Johnson Vision Care
NCT07076160
Clareon PanOptix Pro vs. Clareon PanOptix - Study B
Alcon Research
NCT06401551
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
LENZ Therapeutics
NCT05294328
Comparing the Performance of 1 Day Multifocal Contact Lenses
CooperVision
NCT04449263
Synergy Lens Outcomes Evaluation
Center For Sight
NCT05418153
Apioc Contact Lens Feasibility
Lentechs
NCT03688672
Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients
Johnson & Johnson Vision Care
NCT01016652
Analysis of Defocus Curve of Pre-Presbyopic and Emerging Presbyopic Patients
Vance Thompson Vision
NCT04474782
Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers
Jennifer Fogt
NCT06053463
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
LENZ Therapeutics
NCT02554396
Clinical Validation Study of Comfilcon A Multifocal Toric Contact Lenses
CooperVision
NCT03417557
Assessing the Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Toric Contact Lenses
Alcon Research
NCT05886907
A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses
CooperVision
NCT02719353
A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses
CooperVision
NCT02719366
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Presbyopia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Presbyopia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Presbyopia page
39 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Presbyopia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alcon Research sponsors the most Presbyopia trials on record, review their full trial history before evaluating a specific study. See Alcon Research's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Presbyopia condition card totals 39 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.